Spang & Company to Offer ILUSTRA™ to Employees Through Pittsburgh Business Group on Health Collaboration

WALTHAM, MA – March 13, 2017 – Interleukin Genetics, Inc. (OTCQB: ILIU), a life sciences company focused on the genetics of chronic inflammation, announced today that it has signed an agreement with Spang & Company, a diversified manufacturing company, to offer the ILUSTRA Inflammation Management Program to their employees and their families as an enhancement to the company’s employee benefits plan.

Spang & Company is an employer-member of the Pittsburgh Business Group on Health (PBGH), the region’s leading employer-led coalition and as a member received early access to the ILUSTRA Program. Under the terms of the agreement, ILUSTRA will be made available to all of Spang & Company’s US based employees and their families. Spang & Company is expected to deploy the ILUSTRA Program in May, 2017.

“We are excited to offer this innovative new benefit that integrates the precision of genetic testing with personalized preventative care for our employees and their families,” said Lynne Ellis, Vice President, Human Resources at Spang & Company. “We believe this unique program will provide our employees with access to the best care for improved overall health and wellness. Our membership with PBGH and their collaboration with the ILUSTRA team offers an exciting platform to deploy this unique benefit.”

“We are proud to be working with Spang and with PBGH to expand access to ILUSTRA,” said Mark Carbeau, Chief Executive Officer of Interleukin Genetics. “Working together we expect to demonstrate real value for Spang and its employees and their families, and to share these results through the coalition to the broader membership. We appreciate their collaboration as we advance this program in the region.”

About the ILUSTRA Inflammation Management Program
The ILUSTRA Inflammation Management Program is designed to transform the management of inflammation by targeting individuals with elevated risk for severe periodontitis due to a genetic tendency to over-produce inflammation and directs them to obtain proper dental care. The program integrates three critical components: 1) a genetic risk test to identify patients at risk; 2) targeted education to healthcare professionals to individualize employee care plans; and 3) an 18-month subscription to the ILUSTRA Engagement Platform – a digital program that delivers relevant, personalized content tailored to maximize engagement and drive compliance and behavior change.

Several studies link oral and systemic disease and document the significant impact of enhanced dental care to lower costs of medical management of certain chronic diseases like type 2 diabetes, cardiovascular disease and stroke. ILUSTRA is a proprietary program that has the potential to transform inflammation management by optimizing access to dental care to impact the onset and the progression of chronic diseases, and thereby reducing employer healthcare costs.

The ILUSTRA Inflammation Management Program is made available to employees in covered health plans under the supervision of a licensed dentist or physician. The ILUSTRA test is run solely in Interleukin’s CLIA-certified lab in suburban Boston. For more information, visit

About Spang & Company
Founded in 1894, Spang & Company is a diversified manufacturing company. Through the work of three unique product lines, Spang & Company designs, produces and supplies precision soft magnetic components and materials to the electronics industry, power control equipment for highly critical industrial processes, and custom inductive component design and manufacturing. With headquarters in Pittsburgh, Pennsylvania, Spang & Company provides products and services on a worldwide scale, with sales offices and manufacturing plants around the globe.

About Interleukin Genetics, Inc.
Interleukin Genetics, Inc. (OTCQB: ILIU) develops and markets proprietary genetic tests for chronic inflammatory diseases and health-related conditions, with significant expertise in metabolism and inflammation. Our tests provide information that is not otherwise available, to empower individuals and their healthcare providers to manage their health and wellness through genetics-based insights and actionable guidance, including pharmacogenomics information to guide development and use of therapeutics.  Interleukin Genetics’ lead products include its proprietary ILUSTRA Inflammation Management Program, an integrated program that utilizes a simple genetic test to easily identify patients at elevated risk for developing severe periodontal disease due to a genetic tendency to over-produce inflammation; its cardiovascular test to guide treatment of high risk patients; and its Inherent Health® line of genetic tests. Interleukin Genetics is headquartered in suburban Boston and operates an on-site DNA testing laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit

Forward-Looking Statements
Certain statements contained herein are “forward-looking” statements, including, but not limited to, statements that our ILUSTRA Inflammation Management Program has potential to provide significant health and economic value by improving the management of chronic inflammation and that certain individuals may benefit from enhanced dental care to lower their systemic inflammatory burden by preventing and treating gingivitis and periodontitis and statements about expanding access to the ILUSTRA Program. Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those risks and uncertainties described in Interleukin’s annual report on Form 10-K for the year ended December 31, 2015, and other filings with the Securities and Exchange Commission. Interleukin disclaims any obligation or intention to update these forward-looking statements.

Investor Contact:
Steve DiPalma
Interleukin Genetics, Inc.
(508) 654-4572

Media Contact:
Mary Hiter
Interleukin Genetics, Inc.
(864) 884-6979